






































CLAIMS











1. A compound selected from any one of the following structures, or a pharmaceutically acceptable salt or a deuterated form thereof:


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,

,






























,

,

,

,

,

,

,

,

,

,











,











,











































,

,

,

,

,

,











,

,

,

,

,

,

,Br

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,



2. The compound of claim 1, having the following structure:








or

.

or a pharmaceutically acceptable salt or deuterated form thereof.

3. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or deuterated form thereof.

4. Use of a compound of claim 1 or 2, or a pharmaceutically acceptable salt or deuterated form thereof, in the manufacture of a medicament for treating 5-HT_2A receptor associated disease or disorder.

5. The use of claim 4, wherein the 5-HT_2A receptor associated disease or disorder is an anxiety disorder, attention deficit hyperactivity disorder (ADHD), depression, cluster headache, diminished drive, burn-out, bore-out, migraine, Parkinson's disease, schizophrenia, an eating disorder, psychotic disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar I disorder, bipolar II disorder, major depressive disorder, psychotic depression, delusional disorders, shared psychotic disorder, Shared paranoia disorder, brief psychotic disorder, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, social anxiety disorder, substance-induced anxiety disorder, selective mutism, panic disorder, panic attacks, agoraphobia, posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and premenstrual syndrome (PMS).

6. The use of claim 5, wherein the 5-HT_2A receptor associated disease or disorder is depression

7. The use of claim 6, wherein the depression is treatment resistant depression.

8. The use of claim 5, wherein the 5-HT_2A receptor associated disease or disorder is an eating disorder.

9. The use of claim 8, wherein the eating disorder is anorexia nervosa.

10. The use of claim 5, wherein the 5-HT_2A receptor associated disease or disorder is an anxiety disorder.

11. The use of claim 5, wherein the 5-HT_2A receptor associated disease or disorder is bipolar I disorder.

12. The use of claim 5, wherein the 5-HT_2A receptor associated disease or disorder is bipolar II disorder.

13. The use of claim 5, wherein the 5-HT_2A receptor associated disease or disorder is major depressive disorder.

14. The use of claim 5, wherein the 5-HT_2A receptor associated disease or disorder is posttraumatic stress disorder (PTSD).